Sign in

Johann Morelle

@johannmorelle.bsky.social
533 followers 123 following 32 posts

MD, PhD, FASN | Head of the Division of Nephrology at University Hospitals Namur (www.chuuclnamur.be) | Physician-scientist at de Duve Institute (www.deduveinstitute.be) Special interest in glomerular diseases and TMA

PostsRepliesMedia
Reposted by Johann Morelle
Dominique Guerrot @dguerrot.bsky.social · 31/05/2026
Important metaanalysis presented at #ESH2026 & in The Lancet: In patients with CKD, each 5 mmHg reduction in systolic BP reduced major cardiovascular events by ~9%, with similar relative benefits across CKD stages, proteinuria status and baseline BP levels. linkinghub.elsevier.com/retrieve/pii...
093
Johann Morelle @johannmorelle.bsky.social · 27/05/2026
Infection risk mitigation with complement inhibitors in kidney disease @ndt-era.bsky.social @kronbichlerlab.bsky.social @hjanders.bsky.social academic.oup.com/ndt/article-...
academic.oup.com
Infection risk mitigation with complement inhibitors in kidney disease
Abstract. Complement inhibitors are increasingly used in kidney diseases, ranging from complement-mediated thrombotic microangiopathies to glomerulonephrit
140
Reposted by Johann Morelle
American Journal of Kidney Diseases @ajkd.bsky.social · 06/03/2026
In celebration of #WorldKidneyDay on March 12, this special collection highlights kidney disease research from around the world: bit.ly/3EUhrPN (FREE)
052
Reposted by Johann Morelle
Ardem Patapoutian @ardemp.bskyverified.social · 04/12/2025
A long delay between pre print and publication means this paper only got better and better. Congrats @rose-hill.bsky.social and all collaborators, including many in renal physiology. A role for PIEZO2 in sensing pressure in the kidney and regulating the renin pathway. www.cell.com/cell/fulltex...
cell.com
Renal PIEZO2 is an essential regulator of renin
The force-sensing ion channel PIEZO2 is an essential regulator of the renin-angiotensin-aldosterone system (RAAS), a pathway that controls blood volume. Loss of PIEZO2 in the kidney cells that produce...
3536
Reposted by Johann Morelle
NDT @ndt-era.bsky.social · 01/12/2025
Management of monoclonal gammopathy of renal significance: treatment standard doi.org/10.1093/ndt/...
doi.org
Management of monoclonal gammopathy of renal significance: treatment standard
Abstract. Monoclonal gammopathy of renal significance (MGRS) is a heterogeneous group of clonal B-cell or plasma cell proliferative disorders that cause ki
001
Reposted by Johann Morelle
markusathome @markusathome.bsky.social · 31/10/2025
Stream it now! Our webinar in cooperation with NDT: IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan @ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social youtu.be/l0g9_lkW5_w?...
youtu.be
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
YouTube video by MARKUS at HOMe
085
Reposted by Johann Morelle
Jeff Miner @jeffminerphd.bsky.social · 31/07/2025
Thrilled to have this finally published! If you are interested in learning about the collagen IV diseases Gould syndrome and Alport syndrome, add this to your reading list. www.nature.com/articles/s41...
nature.com
Collagen IV in Gould syndrome and Alport syndrome
Nature Reviews Nephrology - In this Review, the authors focus on the role of collagen IV in Gould syndrome and Alport syndrome. They discuss the molecular and phenotypic similarities and...
53110
Reposted by Johann Morelle
Janewit Wongboonsin @janewit-thekidgene.bsky.social · 19/07/2025
🧬Introducing our first-ever handbook of genetic nephrology, with free download until 8/2025 authors.elsevier.com/a/1lSgWzcYo6... @andrewmallett8.bsky.social and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy
authors.elsevier.com
5199
Reposted by Johann Morelle
Izabela Zakrocka @izabelazakrocka.bsky.social · 07/06/2025
We got it 💪🏻 #ERA25 thank you @rosertorra.bsky.social 👏🏻
072
Reposted by Johann Morelle
Izabela Zakrocka @izabelazakrocka.bsky.social · 06/06/2025
Finding novel antigens in membranous nephropathy through mass spectrometry by @johannmorelle.bsky.social #ERA25
151
Reposted by Johann Morelle
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/06/2025
The first #ERA25 simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip www.nejm.org/doi/full/10....
Urinary Albumin-to-Creatinine Ratio, Serum Potassium Level, Estimated Glomerular Filtration Rate, and Systolic Blood Pressure over Time.
34123
Reposted by Johann Morelle
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 03/06/2025
Congrats to all the @asnkidney.bsky.social lifetime and mid-career awardees! @ksusztak.bsky.social @genetickidneydoc.bsky.social @shinamenon.bsky.social @michellejtx.bsky.social and everyone else!
award winner list
4317
Reposted by Johann Morelle
American Journal of Kidney Diseases @ajkd.bsky.social · 24/05/2025
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy bit.ly/4ccCs4H #OpenAccess #VisualAbstract
031
Reposted by Johann Morelle
NDT @ndt-era.bsky.social · 15/05/2025
Complement activation in secondary thrombotic microangiopathies doi.org/10.1093/ndt/... 👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
043
Johann Morelle @johannmorelle.bsky.social · 16/05/2025
Secondary #TMA represent a major unmet medical need. Grateful for the opportunity to review the role of #complement and discuss when to consider complement inhibitors in these dramatic diseases. 🙏 to outstanding co-authors and the #ERA IWG @kronbichlerlab.bsky.social @ndt-era.bsky.social
052
Reposted by Johann Morelle
Eric Topol @erictopol.bsky.social · 15/05/2025
Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism" —the 1st human to undergo custom genome editing —from decades of NIH funded research www.nejm.org/doi/full/10.... @nejm.org www.nejm.org/doi/full/10.... www.nytimes.com/2025/05/15/h...
10591167
Reposted by Johann Morelle
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 11/05/2025
Beautiful essay from Rajeev Raghavan in the @nejm.org Driving Jackson (a dialysis patient to his clinic appointments) www.nejm.org/doi/full/10.... #NephSky
nejm.org
Driving Jackson | NEJM
When a low-income patient receiving home dialysis misses the bus to the clinic, his nephrologist makes a decision that launches a long-term relationship and brings unexpected meaning into his own life...
2117
Reposted by Johann Morelle
ASN Publications @asnpublications.bsky.social · 07/05/2025
In an article within the #ASNJASN series, Mechanisms of Kidney Diseases, authors examine the link between gold salts, penicillamine, and mercury and membranous nephropathy, aiming to develop new hypotheses on how these substances may promote immune dysregulation. bit.ly/JASN0719
011
Reposted by Johann Morelle
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 03/05/2025
The whole story is surreally fascinating Tim Friede’s YT channel: youtube.com/@timfriede57... The @cellpress.bsky.social paper: www.cell.com/cell/fulltex... A BBC story www.bbc.com/news/article... A universal antivenom would be huge - this seems like a big step
Graphical abstract
1104
Reposted by Johann Morelle
Tiff Caza @glombandit.bsky.social · 03/05/2025
Some take home messages from an inspiring talk by @nephrorock.bsky.social at @kidneycon.bsky.social !
061
Reposted by Johann Morelle
Cristina Popa @nephroseeker.medsky.social · 29/04/2025
🔥 Happening tonight #nephjc
033
Johann Morelle @johannmorelle.bsky.social · 29/04/2025
🔥 Final (pdf) version available online (free): Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy @ajkd.bsky.social ➡️ doi.org/10.1053/j.aj... #OpenAccess 🙏 to all collaborators and sponsors!
153
Reposted by Johann Morelle
NEJM.org @nejm.org · 23/04/2025
In the Advance-HTN phase 2b trial of the aldosterone synthase inhibitor lorundrostat in participants with uncontrolled hypertension, lorundrostat was associated with greater reductions in blood pressure than placebo. Full trial results: nej.md/4ipbCIf #MedSky #CardioSky
A graph showing the least-squares mean changes from baseline (randomization) in the 24-hour average ambulatory systolic blood pressure at 12 weeks.
1149
Reposted by Johann Morelle
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 23/04/2025
The ASIs have arrived www.nejm.org/doi/full/10.... Aldosterone synthase inhibitors - first one to finish the phase 3 line #Lorundrostat #Hypertension
nejm.org
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM
Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...
33727
Reposted by Johann Morelle
Eric Topol @erictopol.bsky.social · 24/04/2025
Why you should know your viral exposure status (i.e CMV) if you're going to undergo immunotherapy for cancer (but almost no one knows) www.nature.com/articles/s41...
nature.com
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade - Nature Medicine
Analysis of multiple cohorts of patients with melanoma demonstrates a positive association between cytomegalovirus serostatus and overall survival in patients treated with monotherapy but not combinat...
521361
Reposted by Johann Morelle
Pierre Delanaye @delanaye.bsky.social · 21/04/2025
EKFC equation to estimate GFR from creatinine and cystatin C, you freely use this link ekfccalculator.pages.dev
ekfccalculator.pages.dev
001
Reposted by Johann Morelle
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 15/04/2025
Sparsentan as First-Line Treatment of Incident Patients with IgAN: Interim Analysis of the SPARTAN Trial #Nephpearls #NKFClinicals 🇺🇸 #NephSky 📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data
154
Reposted by Johann Morelle
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 11/04/2025
DUPLEX Posthoc: Antiproteinuric and nephroprotective benefits of Sparsentan in patients with FSGS #Nephpearls #NKFClinicals 🇺🇸 #NephSky
121
Reposted by Johann Morelle
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 11/04/2025
PARASOL ☂️: Achieving proteinuria <0.7 g/g is associated with meaningful reduction in kidney failure risk in FSGS #Nephpearls #NKFClinicals #NephSky
031
Reposted by Johann Morelle
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 11/04/2025
Sparsentan (DEARA) and FSGS #Nephpearls #NKFClinicals #NephSky
072
Reposted by Johann Morelle
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 10/04/2025
Ultra rapid prednisone taper (median 14 days!) in ANCA vasculitis from the Imperial group www.kireports.org/article/S246... in @kireports.bsky.social #NephSky
Table 1 of prednisone regimen
1124
Reposted by Johann Morelle
Sayna Norouzi, MD @saynanorouzi.bsky.social · 04/04/2025
The FDA approved inebilizumab-cdon (UPLIZNA; @Amgen as the first and only treatment for adult patients diagnosed with immunoglobulin G4-related disease (IgG4-RD). #RareDiseases pubmed.ncbi.nlm.nih.gov/39969992/
pubmed.ncbi.nlm.nih.gov
IgG4-Related Kidney Disease - PubMed
IgG4-Related Kidney Disease
042
Reposted by Johann Morelle
Cristina Popa @nephroseeker.medsky.social · 03/04/2025
Interesting paper @asnpublications.bsky.social ​SGLT2 inhibitors prevent kidney magnesium loss caused by cisplatin #flozins improve Mg reabsorption in the thick ascending limb and distal convoluted tubule VA by @corinateodosiu.bsky.social #nephsky #medsky journals.lww.com/jasn/abstrac...
01911
Reposted by Johann Morelle
American Journal of Kidney Diseases @ajkd.bsky.social · 31/03/2025
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy bit.ly/4ccCs4H #OpenAccess #VisualAbstract
071
Johann Morelle @johannmorelle.bsky.social · 31/03/2025
Grateful for the opportunity to work with such a team — to expand the original technique of laser capture microdissection and mass spectrometry for the identification of target antigens in membranous nephropathy ✨
052
Reposted by Johann Morelle
Eric Topol @erictopol.bsky.social · 29/03/2025
Oral Ozempic reduced major adverse cardiovascular events in a large randomized trial of 9,650 participants with T2 diabetes and high-risk @nejm.org #ACC25 www.nejm.org/doi/full/10....
34897135
Reposted by Johann Morelle
Cristina Popa @nephroseeker.medsky.social · 30/03/2025
FRESH-UP Trial #ACC25 #medsky RCT comparing liberal vs restricted fluid intake (≤1500 ml/d) in 504 pts with stable chronic HF 🌊No difference in status health quantified by Kansas City Cardiomyopathy Questionnaire at 3 mths 🌊 More thirst distress with restriction www.nature.com/articles/s41...
02415
Reposted by Johann Morelle
Joel Topf @kidneyboy.bsky.social · 31/03/2025
People look at this and scream about getting an AV accesses because of the dramatically lower infection rate, but 1.2 infections per 100 patient-years is 1.2 blood stream infections per patient per 8.8 years We have bigger fish to fry in dialysis than one BSI per decade.
2187
Reposted by Johann Morelle
Matthew Sparks @nephrosparks.bsky.social · 21/03/2025
congrats to Novartis for receiving FDA approval for iptacopan for C3G. What an amazing era to start having therapies www.novartis.com/news/media-r...
novartis.com
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
082
Reposted by Johann Morelle
Eric Topol @erictopol.bsky.social · 20/03/2025
"In labs around the world, scientists are using A.I. to search among existing medicines for treatments that work for rare diseases." And saving some lives. @davidfajgenbaum.bsky.social gift link www.nytimes.com/2025/03/20/w...
nytimes.com
Drugs Have Uses We Can’t Imagine. He’s Using A.I. to Find Them. (Gift Article)
Scientists are using machine learning to find new treatments among thousands of old medicines.
1422148
Reposted by Johann Morelle
Krzysztof Kiryluk @kirylukk.bsky.social · 16/03/2025
Nice to see this in print - combined analysis of #CureGN and #CRIC demonstrates the value of broad family history collection from patients with various forms of CKD. Interestingly, positive family history of diabetes was associated with a higher risk of CKD progression even in non-diabetics!
064
Reposted by Johann Morelle
Kenar Jhaveri, MD @kdjhaveri.bsky.social · 14/03/2025
www.era-online.org/publications... #podocytepuzzles
era-online.org
Thrombotic Microangiopathy | ERA
011
Reposted by Johann Morelle
haysamrady @sodatroubles.bsky.social · 12/03/2025
The Utility of Myeloperoxidase Immunostaining to Characterize Immune Deposits in Patients with Crescentic #Glomerulonephritis #nephsky www.kireports.org/article/S246...
kireports.org
The Utility of Myeloperoxidase Immunostaining to Characterize Immune Deposits in Patients with Crescentic Glomerulonephritis
Pauci-immune crescentic glomerulonephritis (GN) is nearly synonymous with anti-neutrophil cytoplasmic antibody (ANCA) associated disease. Cases with immune complex deposition create a diagnostic conun...
022
Reposted by Johann Morelle
Eric Topol @erictopol.bsky.social · 10/03/2025
Multiple sclerosis requires Epstein-Barr virus infection as an underpinning, exhibits self-directed antibodies to EBNA1, the virus's nuclear antigen, representing molecular mimicry. This combines with/ genetic risk factors (Figure, compared w/healthy controls) @pnas.org www.pnas.org/doi/epub/10....
13423113
Johann Morelle @johannmorelle.bsky.social · 09/03/2025
1/ Thrilled to share our latest work ‘Mass Spectrometry with Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy’, just published in @ajkd.bsky.social www.ajkd.org/article/S027... #CHUUCLNamur #deDuveInstitute @inserm.fr #UCLouvain #CuSL A thread
ajkd.org
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
In recent years, the strategy of using laser microdissection and mass spectrometry (LCM/MS) has expanded the landscape of antigens associated with membranous nephropathy (MN). Specific associations wi...
195
Reposted by Johann Morelle
Adam Grant @adamgrant.bsky.social · 09/03/2025
People who can’t handle criticism are unfit to lead. Weak leaders fear dissent as a threat to their power. They silence their critics to shield their egos. Strong leaders welcome dissent as an opportunity for growth. They silence their egos to learn from their critics.
1348390
Reposted by Johann Morelle
Eric Topol @erictopol.bsky.social · 09/03/2025
Research support for rare diseases, which cumulatively affect ~30 million Americans, is primarily derived from NIH. Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast. Open-access, w/ transcript, video, no ads erictopol.substack.com/p/anna-greka...
erictopol.substack.com
Anna Greka: Molecular Sleuthing for Rare Diseases
Listen now | Finding the Mechanisms and the Basis for Potential Cures
331275
Reposted by Johann Morelle
haysamrady @sodatroubles.bsky.social · 07/03/2025
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy #nephsky www.ajkd.org/article/S027...
ajkd.org
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
In recent years, the strategy of using laser microdissection and mass spectrometry (LCM/MS) has expanded the landscape of antigens associated with membranous nephropathy (MN). Specific associations with phenotypes, diseases and sometimes reversible triggers led to an antigen-based classification of MN, informing precision medicine and highlighting for the potential value of routine use of proteomics in classifying MN. This study aimed at reproducing and further improving the original LCM/MS for antigen detection in MN.
064
Reposted by Johann Morelle
Nayan Arora @captainchloride.bsky.social · 07/03/2025
So maybe we don’t need to hold flozins before surgery after all? jamanetwork.com/journals/jam...
jamanetwork.com
11910
Reposted by Johann Morelle
KDIGO @kdigo.org · 07/03/2025
📢 Check out the final report from the KDIGO CKD-MBD Controversies Conference, published in the March issue of Kidney International! Explore key insights on osteoporosis, vascular calcification, and cardiovascular disease in CKD. 🔗 Read the report in KI: kdigo.co/2025-CKD-MBD... #CKDMBD
1104